UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 178

Sortiert nach

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Leukemia, 2020-08, Vol.34 (8), p.2125-2137

2020

Volltextzugriff (PDF)

Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome

Leukemia, 2009-04, Vol.23 (4), p.664-672

2009

Volltextzugriff (PDF)

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

Leukemia, 2009-08, Vol.23 (8), p.1515-1527

2009

Volltextzugriff (PDF)

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

Bone marrow transplantation (Basingstoke), 2014-05, Vol.49 (5), p.684-690

2014

Volltextzugriff (PDF)

Effects of MSC Coadministration and Route of Delivery on Cord Blood Hematopoietic Stem Cell Engraftment

Cell transplantation, 2013-01, Vol.22 (7), p.1171-1183

2013

Volltextzugriff (PDF)

Effect of vitamin D treatment in chronic GVHD

Bone marrow transplantation (Basingstoke), 2011-10, Vol.46 (10), p.1395-1397

2011

Volltextzugriff (PDF)

P1361: TREATMENT OF SEVERE STEROID‐REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE‐BLIND MULTI‐CENTER HOVON‐113 TRIAL

HemaSphere, 2022-06, Vol.6 (Suppl), p.1245-1246

2022

Volltextzugriff (PDF)

Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs

Bone marrow transplantation (Basingstoke), 2011-07, Vol.46 (7), p.1035-1036

2011

Volltextzugriff (PDF)

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

Haematologica (Roma), 2008-09, Vol.93 (9), p.1301-1309

2008

Volltextzugriff (PDF)

Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

Haematologica (Roma), 2012-08, Vol.97 (8), p.1218-1224

2012

Volltextzugriff (PDF)

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

Bone marrow transplantation (Basingstoke), 2019-05, Vol.54 (5), p.757-761

2019

Volltextzugriff (PDF)

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

Bone marrow transplantation (Basingstoke), 2023-06, Vol.58 (6), p.659-666

2023

Volltextzugriff (PDF)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Annals of hematology, 2022-10, Vol.101 (10), p.2263-2270

2022

Volltextzugriff (PDF)

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

Haematologica (Roma), 2013-03, Vol.98 (3), p.437-443

2013

Volltextzugriff (PDF)

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

Leukemia research, 2015-08, Vol.39 (8), p.828-834

2015

Volltextzugriff (PDF)

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST‐ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST‐ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN

HemaSphere, 2022-06, Vol.6 (Suppl), p.731-732

2022

Volltextzugriff (PDF)

Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation

Bone marrow transplantation (Basingstoke), 2006-12, Vol.38 (12), p.821-822

2006

Volltextzugriff (PDF)

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study

Bone marrow transplantation (Basingstoke), 2016-11, Vol.51 (11), p.1524-1526

2016

Volltextzugriff (PDF)

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

Biology of blood and marrow transplantation, 2018-11, Vol.24 (11), p.2365-2370

2018

Volltextzugriff (PDF)

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

The New England journal of medicine, 2013-11, Vol.369 (19), p.1783-1796

2013

Volltextzugriff (PDF)

Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high‐risk non‐Hodgkin B lymphoma patients: A GELTAMO trial

Hematological oncology, 2017-06, Vol.35 (S2), p.346-347

2017

Volltextzugriff (PDF)

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Leukemia research, 2015-03, Vol.39 (3), p.296-306

2015

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Steroid Biochemistry And Molecular Biology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(161)
Mit Volltextzugriff
(137)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q− syndrome

Mesenchymal stem cells from multiple myeloma patients display distinct genomic profile as compared with those from normal donors

Risk factors for thrombotic microangiopathy in allogeneic hematopoietic stem cell recipients receiving GVHD prophylaxis with tacrolimus plus MTX or sirolimus

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Effects of MSC Coadministration and Route of Delivery on Cord Blood Hematopoietic Stem Cell Engraftment

Effect of vitamin D treatment in chronic GVHD

P1361: TREATMENT OF SEVERE STEROID‐REFRACTORY ACUTE GVHD WITH MESENCHYMAL STROMAL CELLS: RESULTS OF THE PHASE III RANDOMIZED DOUBLE‐BLIND MULTI‐CENTER HOVON‐113 TRIAL

Ischemic stroke associated with the infusion of DMSO-cryopreserved auto-PBSCs

The effect of mesenchymal stem cells on the viability, proliferation and differentiation of B-lymphocytes

Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients

Usefulness of eltrombopag for treating thrombocytopenia after allogeneic stem cell transplantation

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)

Real-life analysis on safety and efficacy of asciminib for ponatinib pretreated patients with chronic myeloid leukemia

Analysis of incidence, risk factors and clinical outcome of thromboembolic and bleeding events in 431 allogeneic hematopoietic stem cell transplantation recipients

Influence of donor age in allogeneic stem cell transplant outcome in acute myeloid leukemia and myelodisplastic syndrome

P837: ELTROMBOPAG (EPAG) INDUCES HEMATOLOGIC RESPONSES FOR PATIENTS WITH POST‐ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANT POOR GRAFT FUNCTION (POST‐ALLO HSCT PGF): RESULTS OF THE ELTION STUDY IN SPAIN

Complete remission of subcutaneous panniculitic T-cell lymphoma after allogeneic transplantation

Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)

GvHD prophylaxis with tacrolimus plus sirolimus after reduced intensity conditioning allogeneic transplantation: results of a multicenter study

Immune effector cell-associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations

Manufacturing Mesenchymal Stromal Cells for the Treatment of Graft-versus-Host Disease: A Survey among Centers Affiliated with the European Society for Blood and Marrow Transplantation

A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

Results of a prospective phase II trial with ofatumumab as part of reduced intensity conditioning regimen in high‐risk non‐Hodgkin B lymphoma patients: A GELTAMO trial

Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction

Aktive Filter

Suchergebnisse filtern